tetano
Editor, Senior Moderator
BMC Neurol
. 2022 Aug 22;22(1):309.
doi: 10.1186/s12883-022-02838-4.
A case of Miller Fisher syndrome with delayed onset peripheral facial nerve palsy after COVID-19 vaccination: a case report
Kentaro Nanatsue[SUP] 1 [/SUP], Makoto Takahashi[SUP] 2 [/SUP], Sakiko Itaya[SUP] 1 [/SUP], Keisuke Abe[SUP] 1 [/SUP], Akira Inaba[SUP] 1 [/SUP]
Affiliations
Abstract
Background: To prevent the spread of the novel coronavirus disease 2019 (COVID-19) infection, various vaccines have been developed and used in a large number of people worldwide. One of the most commonly used vaccines is the mRNA vaccine developed by Moderna. Although several studies have shown this vaccine to be safe, the full extent of its side effects has not yet been known. Miller-Fisher syndrome (MFS) is a rare condition that manifests ophthalmoplegia, ataxia, and loss of tendon reflexes. It is a subtype of Guillain-Barré syndrome and an immune-mediated disease related to serum IgG anti-GQ1b antibodies. Several vaccines including those for COVID-19 have been reported to induce MFS. However, there have been no reports of MFS following Moderna COVID-19 vaccine administration.
Case presentation: A 70-year-old man was referred to our hospital due to diplopia that manifested 1 week after receiving the second Moderna vaccine dose. The patient presented with restricted abduction of both eyes, mild ataxia, and loss of tendon reflexes. He was diagnosed with MFS based on his neurological findings and detection of serum anti-GQ1b antibodies. The patient was administered intravenous immunoglobulin, and his symptoms gradually improved. Five days after admission, the patient showed peripheral facial paralysis on the right side. This symptom was suggested to be a delayed onset of peripheral facial nerve palsy following MFS that gradually improved by administration of steroids and antiviral drugs.
Conclusion: There have been no previous reports of MFS after Moderna COVID-19 vaccination. This case may provide new information about the possible neurological side effects of COVID-19 vaccines.
Keywords: Anti-GQ1b antibody; Bell’s palsy; COVID-19; Case report; Fisher syndrome; IVIg; Miller Fisher syndrome; Moderna; Post-vaccination.
. 2022 Aug 22;22(1):309.
doi: 10.1186/s12883-022-02838-4.
A case of Miller Fisher syndrome with delayed onset peripheral facial nerve palsy after COVID-19 vaccination: a case report
Kentaro Nanatsue[SUP] 1 [/SUP], Makoto Takahashi[SUP] 2 [/SUP], Sakiko Itaya[SUP] 1 [/SUP], Keisuke Abe[SUP] 1 [/SUP], Akira Inaba[SUP] 1 [/SUP]
Affiliations
- PMID: 35996074
- DOI: 10.1186/s12883-022-02838-4
Abstract
Background: To prevent the spread of the novel coronavirus disease 2019 (COVID-19) infection, various vaccines have been developed and used in a large number of people worldwide. One of the most commonly used vaccines is the mRNA vaccine developed by Moderna. Although several studies have shown this vaccine to be safe, the full extent of its side effects has not yet been known. Miller-Fisher syndrome (MFS) is a rare condition that manifests ophthalmoplegia, ataxia, and loss of tendon reflexes. It is a subtype of Guillain-Barré syndrome and an immune-mediated disease related to serum IgG anti-GQ1b antibodies. Several vaccines including those for COVID-19 have been reported to induce MFS. However, there have been no reports of MFS following Moderna COVID-19 vaccine administration.
Case presentation: A 70-year-old man was referred to our hospital due to diplopia that manifested 1 week after receiving the second Moderna vaccine dose. The patient presented with restricted abduction of both eyes, mild ataxia, and loss of tendon reflexes. He was diagnosed with MFS based on his neurological findings and detection of serum anti-GQ1b antibodies. The patient was administered intravenous immunoglobulin, and his symptoms gradually improved. Five days after admission, the patient showed peripheral facial paralysis on the right side. This symptom was suggested to be a delayed onset of peripheral facial nerve palsy following MFS that gradually improved by administration of steroids and antiviral drugs.
Conclusion: There have been no previous reports of MFS after Moderna COVID-19 vaccination. This case may provide new information about the possible neurological side effects of COVID-19 vaccines.
Keywords: Anti-GQ1b antibody; Bell’s palsy; COVID-19; Case report; Fisher syndrome; IVIg; Miller Fisher syndrome; Moderna; Post-vaccination.